符合线路^(18)F-脱氧葡萄糖代谢显像在卵巢癌复发中的应用  

Application of ^(18)F-FDG coincidence SPECT detection in diagnosis of the recurrent ovarian cancer

作　　者：陆涤宇[1] 王志[1] 乔雪玲[1] 

机构地区：[1]武汉市中心医院核医学科,武汉430014

出　　处：《临床血液学杂志（输血与检验）》2009年第5期539-541,共3页Journal of Clinical Hematology(Blood Transfusion & Laboratory Medicine)

摘　　要：目的:探讨符合线路18F-脱氧葡萄糖代谢显像(符合线路18F-FDG)在卵巢癌复发中的诊断价值。方法:对40例在核医学科接受符合线路18F-FDG显像的卵巢癌术后患者进行分析,并与CA125进行比较。结果:40例临床疑有复发的卵巢癌患者中,经临床或病理证实复发28例,24/28例符合线路18F-FDG显示阳性;22/28例血清CAI25升高。符合线路18F-FDG显像,CA125监测卵巢癌复发和转移的灵敏度、特异性和准确性分别为85.7%、66.7%和80%;78.6%、83.3%和80%。结论:符合线路18F-FDG显像作为无创伤性检查技术,能及时探测到复发或扩散肿瘤的代谢变化,可以为卵巢癌术后随访,特别是CA125升高的患者提供一种有效的非侵入性影像学诊断方法。Objective：To investigate the value of 18F-FDG coincidence SPECT detection in diagnosis of the recurrent ovarian cancer. Method.18 F-FDG coincidence SPECT detection were performed in 40 patients with ovarian cancer surgery history and compared with serum Ca-125 level. Result： In 28 patients who had recurrent ovarian cancer proved by histology, 24 patients had positive results of 18F-FDG coincidence SPECT detection, 22 patients had increased serum Ca-125 levels. The sensitivity, specificity and accuracy of 18F-FDG coincidence SPECT detection and Serum CA125 for ovarian cancer were 85.7%,66.7%,80% and 78.6%,83.3%,80%,respectively. Conclusion：18F-FDG coincidence SPECT detection could show important value in the diagnosis of recurrent ovarian cancer,especially for patients who serum Ca-125 levels were higher than 35u/ml.

关 键 词：符合线路 18F—FDG CA125 卵巢癌 复发 诊断 

分 类 号：R730.44[医药卫生—肿瘤]